

REMARKS

This response is further to the Amendment filed April 6, 2009.

As discussed with Examiner Graser on April 7, 2009, due to technical problems with the USPTO electronic filing system, only the following documents were provided in the Appendix of the Amendment:

- Clinical Trials.gov. U.S. National Institute of Health, Study Summaries ("HIV Vaccine Trial in Thai Adults", "Phase 1 Safety Study of Two Experimental HIV Vaccines", "HIV-1 Vaccine Test in Uninfected Adult Volunteers").

- Nextbio.com. Clinical Trial > Reactogenicity and Immunogenicity of Vaginal ZM96gp 140.

This response includes the remaining documents listed in the Appendix of the previously filed amendment.

Should there be any matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number listed below.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any

overpayment to our credit card which is being paid online simultaneously herewith for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON

/Robert A. Madsen/

Robert A. Madsen, Reg. No. 58,543
209 Madison Street, Suite 500
Alexandria, VA 22314
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

RAM/mjr

APPENDIX:

The Appendix includes the following item(s):

- Buetow, L. et al., "Structure of the Rho-activating domain of *Escherichia coli* cytotoxic necrotizing factor 1", Nature Structural Biology, Vol. 8, No. 7, July 2001, pp. 584-588.
- Gahéry-Ségard, H. et al., "Multiepitopic B- and T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine", Journal of Virology, Vol. 74, No. 4, Feb. 2000, pp. 1694-1703.
- Gahéry-Ségard, H. et al., "Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized", Journal of Virology, Vol. 77, No. 20, Oct. 2003, pp. 11220-11231.
- Clumeck, N. et al., (Oral Presentation) "Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study", Retrovirology, page 1 of 1.
- Meeting Abstracts, International Meeting of the Institute of Human Virology, Baltimore, MD (Sept. 9-13, 2001; Sept. 10-15, 2000)

- Gringeri, A. et al., "Safety and Immunogenicity of HIV-1 Tat Toxoid in Immunocompromised HIV-1-Infected Patients", Journal of Human Virology, Vol. 1, No. 4, May/June 1998, pp. 293-298.
- Clinical Trials.gov. U.S. National Institute of Health, Study Summaries ("HIV Vaccine Trial in Thai Adults", "Phase 1 Safety Study of Two Experimental HIV Vaccines", "HIV-1 Vaccine Test in Uninfected Adult Volunteers").
- Nextbio.com. Clinical Trial > Reactogenicity and Immunogenicity of Vaginal ZM96gp 140.